Short Interest in Femasys Inc. (NASDAQ:FEMY) Increases By 120.9%

Femasys Inc. (NASDAQ:FEMY) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 658,900 shares, an increase of 120.9% from the February 13th total of 298,300 shares. Based on an average trading volume of 270,500 shares, the short-interest ratio is presently 2.4 days. Approximately 3.4% of the company’s shares are short sold.

Institutional Investors Weigh In On Femasys

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in Femasys during the 4th quarter worth $25,000. Aljian Capital Management LLC bought a new stake in shares of Femasys in the 3rd quarter worth about $27,000. Jane Street Group LLC bought a new stake in shares of Femasys in the 4th quarter worth about $30,000. XTX Topco Ltd increased its position in shares of Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Femasys in the 4th quarter worth about $45,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Femasys in a research note on Thursday.

Femasys Stock Performance

Femasys stock opened at $1.40 on Friday. Femasys has a 12-month low of $0.86 and a 12-month high of $2.12. The company has a market capitalization of $32.06 million, a price-to-earnings ratio of -1.73 and a beta of -2.86. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. The firm’s fifty day moving average price is $1.31 and its 200 day moving average price is $1.19.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.